Switzerland · Delayed Price · Currency is CHF Galenica AG Earnings Call Transcripts
Fiscal Year 2025
-
Group sales grew 5.5% in 2025, with EBIT up 11.3% and strong cash flow supporting a 20% dividend increase. Strategic acquisitions, digital expansion, and efficiency gains drive positive 2026 guidance, despite ongoing price pressure and ERP transition delays.
-
Transformation is driven by culture, digitalization, and staff engagement, with major investments in logistics, diagnostics, and omni-channel pharmacy services. Growth is targeted through innovation, acquisitions, and efficiency, while regulatory changes and market trends are actively managed.
-
Sales grew 5% in H1 2025, with improved profitability and cash flow. Guidance for 2025 is confirmed, with EBIT growth outlook raised to 7%-9% due to one-off effects. The acquisition of Labora Team expands into diagnostics, while market and regulatory pressures remain.
Fiscal Year 2024
-
Solid H1 2024 growth outpaced the market despite weather and IT challenges, with strong performance in products, brands, and local pharmacies. Guidance for 2024 is confirmed, expecting stronger H2 growth, while ERP rollout and high generic substitution rates remain key headwinds.